Furthermore, Neurocrine's lower-than-expected 2025 guidance for Ingrezza—a range of $2.5 billion to $2.6 billion—left investors puzzled and shares spiraling.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the shares. With Ingrezza falling short of Q4 expectations ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43 ...

Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate. Analysts ...